Exchange: NASDAQ·Updated 08:10 AM EDT

INTS INTENSITY THERAPEUTICS, INC.

$4.05
$0.05
(1.25%)
Pre-Market
Prev Close $4.00
Reported EarningsAug 11
Mkt Cap$13.06M
Vol106.00

About INTS

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
58

Bullish Sentiment

How do you feel about INTS?

Advertisement|Remove ads.